First published 9/28/2026, 9:21:15 AM · Last updated 9/28/2026, 9:21:15 AM

Exploratory study to evaluate the combined effect of CBM588: Clostridium butyricum in platinum plus pemetrexed with pembrolizumab for non-small cell lung cancer—protocol of MIYABRO study

This is a published protocol for an exploratory study evaluating CBM588 (Clostridium butyricum) combined with platinum+pemetrexed and pembrolizumab for non-small cell lung cancer, published 2026-09-01. The supplied source excerpt contained no additional study details beyond the title and publication metadata.

Categories: science-and-space, public-health, positive-progress

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 5/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 2/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The protocol documents a planned clinical research effort testing a combination treatment for non-small cell lung cancer.

Sources

Exploratory study to evaluate the combined effect of CBM588: Clostridium butyricum in platinum plus pemetrexed with pembrolizumab for non-small cell lung cancer—protocol of MIYABRO study

Report an issue